Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

EPIX | Essa Pharma Inc

Healthcare | Biotechnology | Canada | NASD

Index	-	P/E	-	EPS (ttm)	-0.62	Insider Own	4.18%	Shs Outstand	44.07M	Perf Week	-3.64%
Market Cap	60.64M	Forward P/E	-	EPS next Y	-1.00	Insider Trans	0.00%	Shs Float	19.97M	Perf Month	2.46%
Income	-27.42M	PEG	-	EPS next Q	-0.22	Inst Own	-	Short Float / Ratio	0.14% / 0.91	Perf Quarter	-2.68%
Sales	0.00M	P/S	-	EPS this Y	13.13%	Inst Trans	-11.55%	Short Interest	0.03M	Perf Half Y	3.93%
Book/sh	3.41	P/B	0.85	EPS next Y	-43.53%	ROA	-16.66%	Target Price	18.50	Perf Year	64.41%
Cash/sh	7.32	P/C	0.40	EPS next 5Y	-	ROE	-17.05%	52W Range	1.40 - 5.16	Perf YTD	15.48%
Dividend	-	P/FCF	-	EPS past 5Y	58.12%	ROI	-18.25%	52W High	-43.60%	Beta	2.10
Dividend %	-	Quick Ratio	44.98	Sales past 5Y	0.00%	Gross Margin	-	52W Low	107.86%	ATR	0.27
Employees	-	Current Ratio	44.98	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	50.24	Volatility	10.11% 9.39%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	17.37%	Profit Margin	-	Rel Volume	2.69	Prev Close	2.88
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 08 BMO	Payout	-	Avg Volume	31.46K	Price	2.91
Recom	1.00	SMA20	1.52%	SMA50	0.88%	SMA200	0.48%	Volume	84,676	Change	1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-23	Resumed	Oppenheimer	Outperform	$17
Mar-04-21	Initiated	Piper Sandler	Overweight	$50
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$10 → $17
Nov-02-20	Initiated	Jefferies	Buy	$17
Oct-25-19	Initiated	Oppenheimer	Outperform	$8

Sep-18-23 07:00AM	ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Aug-31-23 07:00AM	ESSA Pharma Insiders Establish Automatic Securities Disposition Plans (PR Newswire)
Aug-14-23 08:43AM	EPIX: Phase 2 Trial of EPI-7386 in Combination with Enzalutamide to Initiate in Calendar 3Q23 (Zacks) +6.57%
Aug-08-23 07:17AM	ESSA Pharma: Fiscal Q3 Earnings Snapshot (AP Finance)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023 (PR Newswire)
07:00AM	Loading…
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023 (CNW Group)
Jun-06-23 07:00AM	ESSA Pharma Appoints Lauren Merendino to its Board of Directors (PR Newswire)
07:00AM	ESSA Pharma Appoints Lauren Merendino to its Board of Directors (CNW Group)
Jun-01-23 07:00AM	ESSA Pharma to Present at 2023 Jefferies Healthcare Conference (PR Newswire)
07:00AM	ESSA Pharma to Present at 2023 Jefferies Healthcare Conference (CNW Group)
May-24-23 11:04AM	We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely (Simply Wall St.)
May-18-23 06:25AM	EPIX: Moving Towards Phase 2 Trial of EPI-7386 in Combination with Enzalutamide (Zacks Small Cap Research)
May-11-23 07:00AM	ESSA Pharma to Present at JMP Securities Life Sciences Conference (PR Newswire) +6.43%
07:00AM	ESSA Pharma to Present at JMP Securities Life Sciences Conference (CNW Group)
May-09-23 07:19AM	ESSA Pharma: Fiscal Q2 Earnings Snapshot (AP Finance)
07:00AM	Loading…
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023 (PR Newswire)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023 (CNW Group)
Apr-18-23 07:00AM	ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
07:00AM	ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (CNW Group)
Apr-12-23 07:00AM	ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer (PR Newswire) -5.82%
07:00AM	ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer (CNW Group)
Mar-08-23 07:00AM	ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
07:00AM	ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference (CNW Group)
Mar-07-23 05:19AM	ESSA Pharma Inc.'s (NASDAQ:EPIX) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Feb-23-23 05:43AM	EPIX: Deep and Sustained PSA Responses in Phase 1/2 Combination Trial of EPI-7386 and Enzalutamide (Zacks Small Cap Research)
Feb-13-23 05:00PM	ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) (PR Newswire) +5.15%
05:00PM	ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) (CNW Group)
Feb-07-23 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022 (PR Newswire)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022 (CNW Group)
Feb-02-23 04:01PM	ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference (PR Newswire) +6.52%
04:01PM	Loading…
04:01PM	ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference (CNW Group)
Jan-25-23 05:39AM	A Look At The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX) (Simply Wall St.) -5.50%
Jan-06-23 07:04AM	Daily Vickers Top Buyers & Sellers for 01/06/2023 (Argus Research)
Dec-21-22 05:07PM	Examining Penny Stocks with Technical Analysis (Investopedia) -5.91%
Dec-19-22 08:11AM	EPIX: Advancing Multiple Clinical Trials in 2023 (Zacks Small Cap Research)
Dec-15-22 08:30AM	We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate (Simply Wall St.) -5.02%
Dec-13-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022 (CNW Group)
Nov-14-22 09:25AM	EPIX: Promising Early Data for EPI-7386 in Combination with Enzalutamide (Zacks Small Cap Research) -7.90%
Nov-10-22 07:00AM	ESSA Pharma to Participate in Two Upcoming Investor Conferences (PR Newswire) +7.17%
Oct-31-22 11:13AM	ESSA Pharma Shares Tank As Janssen Stops Enrollment In EPI-7386 Combo Prostate Cancer Trials (Benzinga) -18.37%
08:58AM	J&J suspends enrollment in clinical trial assessing Essa Pharma's prostate cancer treatment (MarketWatch)
07:00AM	ESSA Provides an Update on its Clinical Collaboration with Janssen (CNW Group)
Oct-26-22 04:01PM	ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium (PR Newswire) +180.23%
07:00AM	Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat (CNW Group)
Sep-13-22 07:00AM	ESSA Pharma Appoints Philip Kantoff to its Board of Directors (CNW Group)
Aug-10-22 06:40AM	EPIX: Multiple Ongoing Studies of EPI-7386 (Zacks Small Cap Research)
Aug-04-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 (PR Newswire)
Jul-11-22 07:23AM	EPIX: Encouraging Signs of Activity in Phase 1 Trial of EPI-7386 (Zacks Small Cap Research)
Jun-30-22 06:21PM	ESSA Pharma Insiders Establish Automatic Securities Disposition Plans (CNW Group) -9.48%
Jun-28-22 06:29AM	ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer (Benzinga) -9.55%
Jun-27-22 04:01PM	ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development (PR Newswire)
04:01PM	ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development (CNW Group)
Jun-02-22 07:00AM	ESSA Pharma to Present at 2022 Jefferies Healthcare Conference (PR Newswire) +5.64%
07:00AM	ESSA Pharma to Present at 2022 Jefferies Healthcare Conference (CNW Group)
May-27-22 08:12AM	EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22 (Zacks Small Cap Research)
May-10-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022 (PR Newswire) +7.68%
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022 (CNW Group)
Apr-26-22 04:30PM	ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
04:30PM	ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference (CNW Group)
Apr-25-22 10:20AM	EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR (Zacks Small Cap Research)
Apr-08-22 01:00PM	ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders (CNW Group)
Mar-10-22 04:05PM	ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference (PR Newswire)
04:05PM	ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference (CNW Group)
Mar-09-22 11:34PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (PR Newswire)
11:34PM	ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (CNW Group)
Mar-08-22 04:30PM	ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
04:30PM	ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting (CNW Group)
Feb-04-22 05:16AM	EPIX: First Patient Dosed in Combination Trial of EPI-7386 and Enzalutamide (Zacks Small Cap Research) +5.13%
Feb-03-22 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 (PR Newswire)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 (CNW Group)
Jan-19-22 07:00AM	ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) -6.80%
Dec-11-21 05:38AM	Penn Series Small Cap Growth Fund Buys Core & Main Inc, Clear Secure Inc, Inotiv Inc, Sells ... (GuruFocus.com)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Nov-22-21 09:20AM	EPIX: Combination Studies Set to Initiate (Zacks Small Cap Research)
Nov-18-21 07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021 (CNW Group)
Nov-08-21 07:00AM	ESSA Pharma to Participate in Three Upcoming Investor Conferences (PR Newswire)
07:00AM	ESSA Pharma to Participate in Three Upcoming Investor Conferences (CNW Group)
Oct-28-21 04:05PM	ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
04:05PM	ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat (CNW Group)
Oct-19-21 01:21PM	Hedge Funds Are Done Buying ESSA Pharma Inc. (EPIX) (Insider Monkey) +5.13%
Oct-07-21 10:25AM	ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact (Benzinga) +5.03%
09:00AM	ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386 (CNW Group)
06:30AM	Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration (PR Newswire)
Aug-31-21 04:05PM	ESSA Pharma to Present at Upcoming September Investor Conferences (PR Newswire)
04:05PM	ESSA Pharma to Present at Upcoming September Investor Conferences (CNW Group)
Aug-24-21 06:30AM	EPIX: Unwarranted Selloff Following Phase 1 Trial Update (Zacks Small Cap Research) +6.93%
Aug-16-21 02:32PM	Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet (Benzinga) -34.48%
12:13PM	Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump (Benzinga)
10:22AM	Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August (Benzinga)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021 (PR Newswire)
07:00AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021 (CNW Group)
Jul-13-21 12:38PM	Hedge Funds Are Crazy About ESSA Pharma Inc. (EPIX) (Insider Monkey)
May-25-21 07:00AM	ESSA Pharma to Present at the Jefferies Virtual Healthcare Conference (PR Newswire)
May-10-21 10:59AM	EPIX: Combination Trials Upcoming with Astellas, Bayer, and Janssen (Zacks Small Cap Research)
May-06-21 07:01AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021 (PR Newswire)
07:01AM	ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2021 (CNW Group)

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wood David S.	Chief Financial Officer	Dec 30	Buy	2.60	8,302	21,585	33,343	Jan 05 03:07 PM
Parkinson David Ross	Chief Executive Officer	Dec 30	Buy	2.60	3,067	7,974	56,542	Jan 05 06:18 PM
Parkinson David Ross	Chief Executive Officer	Dec 22	Buy	2.39	21,367	51,067	53,475	Jan 05 06:18 PM
BERGER FRANKLIN M	Director	Dec 21	Sale	2.41	72,223	174,401	684,404	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 20	Sale	2.53	43,617	110,351	756,627	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 16	Sale	2.67	50,000	133,500	800,244	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 15	Sale	2.88	82,000	235,800	850,244	Jan 05 03:41 PM
BERGER FRANKLIN M	Director	Dec 14	Sale	3.00	25,000	75,000	932,244	Jan 05 03:41 PM
BIOTECH GROWTH N V	10% Owner	Oct 27	Buy	4.50	500,000	2,251,100	7,879,583	Oct 28 02:57 PM
BIOTECH GROWTH N V	10% Owner	Oct 26	Buy	3.98	1,500,000	5,968,500	7,379,583	Oct 28 02:57 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EPIX | Essa Pharma Inc

Upgrade your FINVIZ experience